Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Rui Wang(Chinese Center For Disease Control and Prevention), Michael Quigley(Scripps Health), Praveen Aanur(Moderna Therapeutics (United States)), Megan Raymond, Ignacio Melero(University of Oxford), Michael Ong(University of California, Los Angeles), Ed Hilt, Dominic Kabbabe, Alan J. Korman(Bristol-Myers Squibb (Germany)), Kent Thudium, Paula M. Fracasso(University of Virginia), Irene Pak, Feng Yan, Gennaro Dito, Anthony J. Olszanski(Fox Chase Cancer Center), Richard D. Carvajal(Northwell Health), Anna Spreafico(University Health Network), Yongliang Sun, Xiao Shao, Chan Gao(Zhejiang Chinese Medical University), Martin Gutierrez(Hackensack University Medical Center), Shih-Min A. Huang(Novartis (Switzerland)), Christina Milburn
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Cytokines in clinical cancer immunotherapy
|British Journal of Cancer|2018|1.2k